Special Issue

Genomic Analysis of Thyroid Carcinoma

Message from the Guest Editor

Previous studies have shown that the occurrence and development of thyroid cancer are affected by many factors, including oncogene mutation, methylation, and copy number increase. Recent studies have also shown that the progression of thyroid cancer is closely related to gene mutations. Thyroid cancer gene mutation is a major cause of thyroid cancer progression, and it is closely related to thyroid cancer diagnosis, prognosis evaluation, surgical planning, and targeted drug therapy. The treatment guidelines for patients with thyroid cancer point out that targeted therapy based on genomic status can effectively prolong the progression-free survival of patients with thyroid cancer, without affecting the quality of life of the patients. The genes of BRAF, TERT, p53, RET, and RAS related to thyroid cancer have been found in succession. However, the clinical significance of those genetic changes in thyroid cancer is still uncertain. Therefore, a more in-depth understanding of the various genetic changes in thyroid patients is crucial for elucidating the pathogenesis and formulating accurate targeted treatment plans.

Guest Editor

Dr. Kyoung Sik Park

Department of Surgery, Konkuk University Medical Centre, Konkuk University School of Medicine, 120 Neungdong-ro, Gwangjin-gu, Seoul 143-729, Republic of Korea

Deadline for manuscript submissions

closed (30 September 2023)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/148856

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

MDPI

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).